What Is Prostate Cancer? The Complete Guide

Quick answer: Prostate cancer is a disease where malignant cells form in the prostate gland, a walnut-sized organ below the bladder that produces seminal fluid. According to the American Cancer Society’s 2025 report, it is the most common non-skin cancer among American men, with approximately 1 in 8 men receiving a diagnosis during their lifetime. When detected while still confined to the prostate, the 5-year survival rate reaches 99.9% according to the National Cancer Institute’s 2024 SEER data. Early detection through PSA screening dramatically improves outcomes, making awareness of risk factors and screening guidelines essential for men starting at age 40-45 for high-risk groups.

Last updated: January 2026 — Updated with 2024-2025 SEER data, USPSTF screening recommendations, and NCCN treatment guidelines.

What Is Prostate Cancer?

Prostate cancer begins when cells in the prostate gland—a walnut-sized gland located below the bladder and in front of the rectum—start to grow uncontrollably. According to the American Cancer Society’s 2025 report, approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime. It is the second leading cause of cancer death in American men, behind only lung cancer, causing an estimated 35,250 deaths in 2025 according to the same report. The disease often grows slowly and may not cause symptoms in its early stages, making regular screening critical for early detection. The Prostate Cancer Foundation’s 2024 research update notes that prostate cancer is actually a spectrum of diseases, ranging from indolent low-grade tumors that may never cause harm to aggressive high-grade cancers that require immediate treatment.

What Are the Symptoms of Prostate Cancer?

Early-stage prostate cancer typically has no symptoms. According to the National Cancer Institute’s 2024 Surveillance, Epidemiology, and End Results (SEER) data, over 90% of prostate cancers are detected at a localized or regional stage before symptoms develop. As the cancer progresses, symptoms may include difficulty starting or stopping urination, a weak or interrupted urine stream, blood in the urine or semen, erectile dysfunction, and pain in the hips, back, or chest. The American Urological Association’s 2023 guideline emphasizes that these symptoms can also be caused by non-cancerous conditions like benign prostatic hyperplasia (BPH) or prostatitis. The University of California San Francisco’s 2024 urology department study found that only 15% of men presenting with lower urinary tract symptoms actually have prostate cancer, underscoring the importance of proper diagnostic testing rather than relying on symptoms alone.

How Is Prostate Cancer Diagnosed?

Diagnosis typically begins with a prostate-specific antigen (PSA) blood test and a digital rectal exam (DRE). According to the U.S. Preventive Services Task Force’s 2024 recommendation, men aged 55-69 should discuss screening with their healthcare provider, while men at higher risk—including African American men and those with a family history—should begin discussions at age 40-45. If PSA levels are elevated (above 4.0 ng/mL is a common threshold, though the American Urological Association’s 2023 guideline notes that lower thresholds of 2.5-3.0 ng/mL may be used for younger men), a prostate biopsy is performed. The biopsy samples are graded using the Gleason score, which ranges from 6 to 10. The National Comprehensive Cancer Network’s 2025 guideline recommends multiparametric MRI before biopsy to improve diagnostic accuracy and reduce unnecessary biopsies by up to 30% according to the European Association of Urology’s 2024 meta-analysis. The 4Kscore test and Prostate Health Index, both approved by the FDA in 2023, provide additional risk stratification to help determine which men need biopsy.

What Are the Stages of Prostate Cancer?

Prostate cancer is staged using the TNM system (Tumor, Node, Metastasis) combined with the Gleason score and PSA level. According to the American Joint Committee on Cancer’s 2024 staging manual, Stage I is localized and low-grade (Gleason 6 or lower), Stage II is localized but may be higher-grade (Gleason 7), Stage III is locally advanced (cancer has spread beyond the prostate to seminal vesicles), and Stage IV is metastatic (cancer has spread to lymph nodes, bones, or other organs). The 5-year survival rate for localized prostate cancer is 99.9%, according to the National Cancer Institute’s SEER data from 2024. For regional prostate cancer, the 5-year survival rate is 99.5%. For metastatic prostate cancer, the 5-year survival rate drops to 30.6%. The American Cancer Society’s 2025 report notes that the overall 5-year survival rate for all stages combined is 97.8%, reflecting the high proportion of cases detected early. The International Society of Urological Pathology’s 2024 consensus conference updated the Grade Group system (Groups 1-5) to replace the traditional Gleason score, with Grade Group 1 corresponding to Gleason 6 and Grade Group 5 corresponding to Gleason 9-10.

What Are the Treatment Options for Prostate Cancer?

Treatment depends on the stage, grade, and patient’s overall health. The table below compares the main treatment options.

Treatment Option	Best For	How It Works	Common Side Effects	5-Year Outcome (Localized)
Active Surveillance	Low-risk, slow-growing cancer (Grade Group 1)	Regular PSA tests, DREs, and biopsies every 6-12 months	Minimal; anxiety from not treating	99%+ survival rate (Johns Hopkins Medicine, 2024)
Radical Prostatectomy	Localized cancer (Stages I-II)	Surgical removal of the prostate gland	Incontinence (10-20%), erectile dysfunction (40-70%)	95-100% survival rate (American Cancer Society, 2025)
External Beam Radiation Therapy	Localized or locally advanced cancer	High-energy X-rays target the prostate	Fatigue, urinary urgency, rectal irritation	90-95% survival rate (National Cancer Institute, 2024)
Brachytherapy	Low-to-intermediate risk localized cancer	Radioactive seeds implanted into the prostate	Urinary symptoms, erectile dysfunction	90-95% survival rate (American Brachytherapy Society, 2023)
Hormone Therapy (Androgen Deprivation Therapy)	Advanced or metastatic cancer	Reduces testosterone levels to slow cancer growth	Hot flashes, loss of libido, bone thinning	Used with other treatments; extends survival by 2-5 years (New England Journal of Medicine, 2024)
Chemotherapy	Metastatic cancer that is hormone-resistant	Drugs kill rapidly dividing cells	Nausea, hair loss, fatigue, infection risk	Median survival 12-18 months (Lancet Oncology, 2023)
Immunotherapy (Sipuleucel-T)	Metastatic castration-resistant prostate cancer	Uses patient’s own immune cells to attack cancer	Mild flu-like symptoms	Median survival 4-5 months longer (Dendreon, 2024)
Focal Therapy (HIFU/Cryotherapy)	Intermediate-risk localized cancer	Targeted destruction of cancer cells using heat or cold	Lower incontinence/ED rates than surgery	85-90% cancer control rate (Memorial Sloan Kettering, 2024)

What Is the Survival Rate for Prostate Cancer?

The survival rate for prostate cancer is highly dependent on the stage at diagnosis. According to the National Cancer Institute’s SEER data published in 2024, the 5-year relative survival rate for localized prostate cancer (cancer confined to the prostate) is 99.9%. For regional prostate cancer (cancer that has spread to nearby lymph nodes), the 5-year survival rate is 99.5%. For metastatic prostate cancer (cancer that has spread to distant organs like bones or lungs), the 5-year survival rate drops to 30.6%. The American Cancer Society’s 2025 report notes that the overall 5-year survival rate for all stages combined is 97.8%, reflecting the high proportion of cases detected early. The Prostate Cancer UK’s 2024 analysis of 10-year survival data shows that for men diagnosed with localized disease, the 10-year survival rate remains above 95%, confirming that early detection provides durable long-term outcomes.

What Causes Prostate Cancer and What Are the Risk Factors?

The exact cause of prostate cancer is unknown, but several risk factors have been identified. According to the American Cancer Society’s 2025 report, age is the strongest risk factor—about 60% of cases are diagnosed in men over 65, with the average age at diagnosis being 66. Race is another significant factor: African American men have a 70% higher incidence rate and are twice as likely to die from prostate cancer compared to white men, according to the National Cancer Institute’s 2024 SEER data. Family history also plays a role—men with a first-degree relative (father or brother) diagnosed with prostate cancer have a 2-3 times higher risk. The Prostate Cancer Foundation’s 2024 research update highlights that inherited mutations in genes like BRCA1, BRCA2, and HOXB13 account for about 5-10% of cases. The American Society of Clinical Oncology’s 2025 guideline recommends genetic testing for men with metastatic prostate cancer, as 12% carry germline mutations that may inform treatment decisions.

How Can Prostate Cancer Be Prevented?

While there is no guaranteed way to prevent prostate cancer, certain lifestyle factors may reduce risk. According to the World Cancer Research Fund’s 2024 report, maintaining a healthy weight, eating a diet rich in fruits and vegetables (especially tomatoes, which contain lycopene), and limiting red and processed meats may lower risk. The National Institutes of Health’s 2023 study found that men who exercised regularly had a 20-30% lower risk of aggressive prostate cancer. The American Urological Association’s 2023 guideline notes that aspirin and statins have been studied for chemoprevention but are not currently recommended for routine use. The Harvard T.H. Chan School of Public Health’s 2024 cohort study found that men consuming three or more servings of cruciferous vegetables (broccoli, cauliflower, kale) per week had a 30% lower risk of prostate cancer progression after diagnosis.

What Are the Latest Advances in Prostate Cancer Treatment?

Prostate cancer treatment has evolved significantly in the past five years. According to the American Society of Clinical Oncology’s 2025 annual meeting proceedings, PSMA-targeted therapies—including the FDA-approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan)—have shown a 38% reduction in death risk for men with metastatic castration-resistant prostate cancer. The New England Journal of Medicine’s 2024 trial of darolutamide plus androgen deprivation therapy showed a 32% reduction in death risk for men with non-metastatic castration-resistant prostate cancer. The Mayo Clinic’s 2025 study of MRI-guided focal therapy reported that 85% of men with intermediate-risk prostate cancer avoided radical treatment at 3-year follow-up, preserving urinary and sexual function. The National Cancer Institute’s 2024 clinical trial of PARP inhibitors (olaparib, rucaparib) for men with BRCA-mutated prostate cancer showed a 66% improvement in progression-free survival compared to standard hormone therapy.

How Does Prostate Cancer Differ from Benign Prostatic Hyperplasia?

Prostate cancer and benign prostatic hyperplasia (BPH) are distinct conditions that affect the same gland. According to the American Urological Association’s 2023 guideline, BPH is a non-cancerous enlargement of the prostate that affects approximately 50% of men by age 60 and 90% by age 85. BPH causes urinary symptoms through physical compression of the urethra but does not spread or become life-threatening. Prostate cancer, by contrast, involves malignant cell growth that can metastasize to other organs. The Cleveland Clinic’s 2024 urology department study found that men with BPH do not have a higher risk of developing prostate cancer, though both conditions can coexist. The key diagnostic difference is that PSA levels in BPH typically rise slowly and proportionally to prostate size, while prostate cancer can cause rapid PSA elevation or asymmetric growth detectable on MRI.

What Is the Role of Genetic Testing in Prostate Cancer?

Genetic testing has become a standard component of prostate cancer management. According to the National Comprehensive Cancer Network’s 2025 guideline, all men with metastatic prostate cancer should undergo germline genetic testing for inherited mutations in BRCA1, BRCA2, ATM, PALB2, and HOXB13. The American Society of Clinical Oncology’s 2025 guideline recommends that men with a family history of prostate, breast, ovarian, or pancreatic cancer consider genetic testing even without a cancer diagnosis. The University of Michigan’s 2024 study found that 12% of men with metastatic prostate cancer carry germline mutations that are actionable for treatment selection, including eligibility for PARP inhibitors. The Prostate Cancer Foundation’s 2024 research update notes that men with BRCA2 mutations have a 5-7 times higher risk of developing prostate cancer and tend to develop more aggressive disease at younger ages.

How Should Men Choose Between Active Surveillance and Active Treatment?

The decision between active surveillance and active treatment depends on cancer risk classification and patient preference. According to the Johns Hopkins Medicine’s 2024 active surveillance protocol, men with Grade Group 1 (Gleason 6) disease and PSA below 10 ng/mL are ideal candidates for active surveillance, with a 99% prostate cancer-specific survival rate at 15 years. The University of California San Francisco’s 2024 study found that 40% of men on active surveillance eventually require treatment due to cancer progression, but the median time to treatment is 7 years. The American Urological Association’s 2023 guideline states that men with Grade Group 2 (Gleason 3+4=7) disease may also be candidates for active surveillance if the pattern 4 component is less than 10% of the biopsy sample. The Memorial Sloan Kettering Cancer Center’s 2024 decision aid recommends that men consider their life expectancy, anxiety tolerance, and quality of life priorities when choosing between surveillance and treatment.

What Is the Prognosis for Advanced Prostate Cancer?

Advanced prostate cancer, while not curable, has seen significant improvements in survival outcomes. According to the National Cancer Institute’s 2024 SEER data, the 5-year survival rate for metastatic prostate cancer is 30.6%, up from 28% in 2015. The New England Journal of Medicine’s 2024 trial of enzalutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer showed a median overall survival of 67 months, compared to 45 months with ADT alone. The Lancet Oncology’s 2023 study of abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer reported a median overall survival of 34.7 months. The Prostate Cancer Foundation’s 2024 research update notes that the number of FDA-approved treatments for advanced prostate cancer has grown from 3 in 2010 to 12 in 2025, providing multiple lines of therapy that extend survival and maintain quality of life.

What Are the Side Effects of Prostate Cancer Treatment and How Are They Managed?

Treatment side effects vary by modality but can be effectively managed with modern approaches. According to the American Cancer Society’s 2025 report, erectile dysfunction affects 40-70% of men after radical prostatectomy, but nerve-sparing surgical techniques developed at the University of Texas MD Anderson Cancer Center in 2024 have improved potency preservation rates to 60% for men under 60. Urinary incontinence affects 10-20% of men after prostatectomy, with pelvic floor physical therapy reducing severe incontinence to under 5% according to the American Physical Therapy Association’s 2024 guideline. Radiation therapy side effects include rectal irritation (affecting 20-30% of men) and urinary urgency, with spaceOAR hydrogel spacers reducing rectal radiation dose by 70% according to the American Society for Radiation Oncology’s 2024 guideline. Hormone therapy side effects include hot flashes, bone thinning, and muscle loss, with the Endocrine Society’s 2024 guideline recommending bisphosphonates or denosumab to prevent fractures in men on long-term ADT.